Cingulate Inc.

The momentum for this stock is not very good. Cingulate Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Cingulate Inc..

News

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Globe Newswire $10 Million of additional Capital Recently Raised Strengthening Balance SheetKANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company...\n more…

What's Going On With Cingulate Shares Recently?

Benzinga Cingulate Inc. (NASDAQ: CING) shares are soaring Friday. the stock is trading with a session volume of 3.297 million shares, approaching its 100-day average volume of 3.654 million shares.\n more…

Q3 2024 Earnings Forecast for Cingulate Inc. Issued By Zacks Small Cap (NASDAQ:CING)

Zolmax Cingulate Inc. (NASDAQ:CING - Free Report) - Equities research analysts at Zacks Small Cap issued their Q3 2024 earnings per share estimates for shares of Cingulate in a research report issued on...\n more…

Short Interest in Cingulate Inc. (NASDAQ:CING) Increases By 521.7%

Ticker Report Cingulate Inc. (NASDAQ:CING - Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 51,600 shares, a growth of 521.7...\n more…

Q3 2024 Earnings Forecast for Cingulate Inc. (NASDAQ:CING) Issued By Zacks Small Cap

Ticker Report Cingulate Inc. (NASDAQ:CING - Free Report) - Stock analysts at Zacks Small Cap issued their Q3 2024 earnings per share estimates for shares of Cingulate in a research note issued to investors on...\n more…

Cingulate to Participate in Benzinga All Live Access Event

Globe Newswire KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR ) drug delivery platform...\n more…